Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and potential post-approval market exclusivity for qualifying rare diseases.

Alcon agreed to buy LENSAR for $14.00/share cash, integrating ALLY, Streamline, and the legacy laser system to expand FLACS ...

Their Perspective article, published in npj Digital Medicine, warns that treating medical artificial intelligence (AI) as an "autopilot" rather than a "digital copilot" risks a dangerous "deskilling" ...

NovaBridge Biosciences and Visara have announced topline results from their phase 2a study of VIS-101 for retinal vascular ...

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...

Commercial rollout includes direct purchasing and specialty distribution, alongside scaled investments in awareness, education, screening, and diagnosis to drive earlier keratoconus detection. Epioxa ...

ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

Physiologic AL varies materially with age, sex, height, and ethnicity, undermining fixed AL thresholds as broadly applicable risk stratifiers in typical pediatric myopia. Retinal pathology risk ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...

Management prioritizes 5%–10% weight loss and acetazolamide titration guided by Frisén grading, OCT, and visual fields; refractory or vision-threatening disease may need ONSF or CSF shunting.